When is it appropriate to restart Adderall (mixed‑amphetamine salts) following psilocybin ingestion?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

When to Restart Adderall After Psilocybin Ingestion

Wait at least 24-48 hours after psilocybin ingestion before restarting Adderall, and only after confirming complete resolution of all acute psychedelic effects and cardiovascular stability.

Critical Safety Considerations

The primary concern is the risk of hypertensive emergency when combining amphetamines with substances that affect serotonergic and adrenergic systems. A 2024 case report documented a myocardial infarction with ST-elevation following the combination of psilocybin mushrooms with extended-release dextroamphetamine-amphetamine 1. While this case involved concurrent MAOI use (tranylcypromine), it highlights the serious cardiovascular risks of combining these substances.

Key Pharmacokinetic Facts

  • Psilocybin's active metabolite (psilocin) has a half-life of approximately 2-3 hours, with acute effects lasting 4-6 hours
  • Adderall contains mixed amphetamine salts that are rapidly absorbed within 30 minutes and have effects lasting 3-4 hours for immediate-release formulations 2
  • Extended-release formulations provide longer duration of action and should be considered when calculating washout periods

Specific Restart Protocol

Before Restarting Adderall:

  1. Confirm complete resolution of psilocybin effects (typically 6-8 hours post-ingestion for subjective effects)
  2. Wait an additional 16-40 hours to ensure complete elimination of psilocybin metabolites and any residual cardiovascular effects
  3. Check vital signs: Blood pressure and heart rate must be at baseline 2, 3
  4. Screen for any persistent symptoms: chest pain, palpitations, headache, or visual changes

Cardiovascular Monitoring

The FDA label for Adderall explicitly warns about risks in patients with cardiac disease and emphasizes monitoring blood pressure and heart rate 3. Given that psilocybin can cause transient hypertension (documented in clinical trials 4), ensure:

  • Blood pressure < 140/90 mmHg
  • Heart rate < 100 bpm at rest
  • No chest pain or palpitations
  • No signs of sympathetic overactivity

Common Pitfalls to Avoid

Do not restart Adderall if:

  • Any residual perceptual changes persist
  • Blood pressure or heart rate remain elevated
  • The patient is taking MAOIs (absolute contraindication - requires 14-day washout) 3
  • Any cardiovascular symptoms are present

Special caution with:

  • Patients with pre-existing cardiac conditions (consider longer washout period of 48-72 hours)
  • Those who consumed large doses of psilocybin (>3.5g dried mushrooms)
  • Concurrent use of other serotonergic medications 3

Clinical Context

While recent research shows psilocybin-assisted therapy may have therapeutic potential for substance use disorders 4, 5, 6, these studies used controlled medical settings with careful screening. The case report of hypertensive emergency 1 suggests that phenylethylamine compounds in psilocybin mushrooms may interact dangerously with amphetamines, particularly when combined with other sympathomimetic or serotonergic agents.

The conservative 24-48 hour waiting period prioritizes patient safety by allowing complete elimination of psilocybin metabolites and normalization of cardiovascular parameters before reintroducing a potent sympathomimetic stimulant. This approach minimizes risk of hypertensive crisis, cardiac arrhythmias, or serotonin syndrome.

If the patient experiences any concerning symptoms during the washout period or upon restarting Adderall (chest pain, severe headache, palpitations, visual changes), discontinue Adderall immediately and seek emergency medical evaluation 3, 1.

References

2
Guideline

practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults.

Journal of the American Academy of Child and Adolescent Psychiatry, 2002

Related Questions

Can lisdexamfetamine (Vyvanse) be taken concomitantly with psilocybin?
Can a generally healthy adult without hypertension, seizure disorder, substance misuse, or MAOI use safely combine bupropion (Wellbutrin) with Adderall (amphetamine/dextroamphetamine)?
For a patient taking levothyroxine and Adderall (mixed amphetamine salts), how far apart should the doses be spaced?
Can Vyvanse (lisdexamfetamine) be used concurrently with a monoamine oxidase inhibitor (MAOI) or how should the medications be safely transitioned?
Is it safe to combine Vyvanse (lisdexamfetamine) with Adderall XR (mixed‑amphetamine salts extended‑release), and how should the dosing be adjusted?
If ductal carcinoma in situ is triple‑positive (ER‑positive, PR‑positive, HER2‑positive), what is the recommended management?
What is the likely cause of monoblasts on a peripheral blood smear in a 54-year-old male presenting with malaise, cough, upper respiratory symptoms, COVID-19 reverse transcription polymerase chain reaction (rRT‑PCR) positivity and pneumonia?
How does a contused lacerated wound (CLW) develop compared to a simple lacerated wound?
I resumed Adderall (amphetamine salts) 36 hours after stopping and now have severe brain fog, fatigue, and dissociative feelings; what should I do?
How should lower leg and foot edema be managed after total hip arthroplasty?
How should a 7 mm incidental upper‑pole renal lesion suspected to be an angiomyolipoma be evaluated and managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.